21 May 2019 - - Several new investors have joined US-based Schrödinger's latest funding round, which was completed with a total raise of USD 110m to support continued advancement of the company's computational platform and expansion of its therapeutic pipeline, the company said.

New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec's Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).

The funding will support the advancement of Schrödinger's wholly-owned drug discovery pipeline and enable continued expansion of the company's collaborations with biopharma companies worldwide.

These partnerships have already led to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programmes moving through discovery and development.

The investment will also support Schrödinger's ongoing research and development efforts to extend the reach of its proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods.

This expanded and accelerated exploration opens new frontiers for discovery of novel compounds for both therapeutic indications and materials design.

Schrödinger has a global business, licensing its computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R and D in both drug discovery and materials design.

The company has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.

Schrödinger's investment in basic research continues to drive advances in its computational platform.

Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world.